Comparative Pharmacology
Head-to-head clinical analysis: QUINIDEX versus TIKOSYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUINIDEX versus TIKOSYN.
QUINIDEX vs TIKOSYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ia antiarrhythmic agent; blocks sodium channels (fast inward sodium current) and prolongs action potential duration; also has anticholinergic and negative inotropic effects.
Selective class III antiarrhythmic agent; blocks cardiac potassium channels (IKr), prolonging action potential duration and effective refractory period.
Quinidine sulfate (QUINIDEX): 200-400 mg orally every 6 hours as arrhythmia suppression; maximum 4 g/day. Route: oral, frequency: every 6 hours.
500 mcg orally twice daily for atrial fibrillation/flutter conversion and maintenance of sinus rhythm.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in adults with normal renal and hepatic function; may be prolonged to 10-12 hours in congestive heart failure or hepatic impairment.
10 hours (terminal) in patients with normal renal function; prolonged to up to 42 hours in severe renal impairment; clinically relevant for dosing interval adjustment.
Renal excretion accounts for approximately 20% unchanged drug; hepatic metabolism (primarily CYP3A4) accounts for 80% with metabolites excreted renally and biliarily; about 5% excreted in feces.
Renal: 80% as unchanged drug; biliary/fecal: 20% (metabolites and minor parent drug).
Category C
Category C
Antiarrhythmic Agent
Antiarrhythmic Agent